Thomas Cahill - Oct 24, 2022 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Director
Signature
/s/ Carman Alenson attorney-in-fact
Stock symbol
PRME
Transactions as of
Oct 24, 2022
Transactions value $
$6,800,000
Form type
4
Date filed
10/26/2022, 08:00 PM
Previous filing
Oct 19, 2022
Next filing
Jun 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRME Common Stock Conversion of derivative security +4.91M 4.91M Oct 24, 2022 By Newpath Partners, L.P. F1, F2
transaction PRME Common Stock Purchase $6.8M +400K +8.15% $17.00 5.31M Oct 24, 2022 By Newpath Partners, L.P. F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Series A Convertible Preferred Stock Conversion of derivative security $0 -10M -100% $0.00* 0 Oct 24, 2022 Common Stock 3.22M By Newpath Partners, L.P. F1, F2
transaction PRME Series B Convertible Preferred Stock Conversion of derivative security $0 -5.25M -100% $0.00* 0 Oct 24, 2022 Common Stock 1.69M By Newpath Partners, L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date.
F2 Represents shares held directly by Newpath Partners, L.P. ("Newpath LP"). Newpath Partners GP, L.P. ("Newpath GP LP") is the general partner of Newpath LP. Newpath Partners GP, LLC ("Newpath GP LLC") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F3 Reflects shares purchased by Newpath LP in the Issuer's initial public offering.